Second Genome Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 14

Employees

  • Latest Deal Type
  • M&A

Second Genome General Information

Description

Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision therapies and biomarkers. The company's platform uses a microbiome data platform that combines genomics technologies, computational biology, and phenotypic screening to identify novel proteins, peptides, and metabolites from the microbiome, enabling researchers to develop medicines through microbiome science.

Contact Information

Formerly Known As
Phylotech
Ownership Status
Privately Held (backing)
Financing Status
Formerly VC-backed
Corporate Office
  • 1000 Marina Boulevard
  • Suite 500
  • Brisbane, CA 94005-1838
  • United States
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Other Healthcare Technology Systems
Vertical(s)
Corporate Office
  • 1000 Marina Boulevard
  • Suite 500
  • Brisbane, CA 94005-1838
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Second Genome Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition Completed Clinical Trials - Phase 2
9. Secondary Transaction - Private 01-Sep-2021 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series B) 15-Mar-2019 Completed Clinical Trials - Phase 2
7. Grant 01-Jan-2019 Completed Startup
6. Accelerator/Incubator 14-Jun-2017 Completed Startup
5. Later Stage VC (Series B) 14-May-2017 Completed Startup
4. Grant 01-Jan-2017 Completed Startup
3. Early Stage VC (Series A) 07-Jun-2013 Completed Startup
2. Early Stage VC (Series A) 09-Aug-2011 $5M $6.24M Completed Startup
1. Seed Round 07-Jul-2010 $1.24M $1.24M Completed Startup
To view Second Genome’s complete valuation and funding history, request access »

Second Genome Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series B
Series A
Seed 5,607,290 $0.000100 $0.02 $0.22 $0.22 1x $0.22 1.45%
To view Second Genome’s complete cap table history, request access »

Second Genome Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a biotechnology platform intended to extract microbial genetic insights to make transformational precision t
Drug Discovery
Brisbane, CA
14 As of 2022

Cambridge, MA
 

Dublin, OH
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Second Genome Competitors (30)

One of Second Genome’s 30 competitors is Vedanta Biosciences, a Venture Capital-Backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Vedanta Biosciences Venture Capital-Backed Cambridge, MA
Biosortia Microbiomics Venture Capital-Backed Dublin, OH
4D pharma Corporation Leeds, United Kingdom
Eligo Bioscience Venture Capital-Backed Paris, France
Sphere Fluidics Formerly VC-backed Cambridge, United Kingdom
You’re viewing 5 of 30 competitors. Get the full list »

Second Genome Patents

Second Genome Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2022256700-A1 Peptides for immunotherapy Inactive 04-Jun-2021
WO-2022093936-A1 Batch processing Inactive 28-Oct-2020
AU-2021367318-A1 Methods for treating autism spectrum disorder Pending 19-Oct-2020
AU-2021367318-A9 Methods for treating autism spectrum disorder Pending 19-Oct-2020
EP-4228666-A1 Methods for treating autism spectrum disorder Pending 19-Oct-2020 A61K35/74
To view Second Genome’s complete patent history, request access »

Second Genome Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Second Genome FAQs

  • When was Second Genome founded?

    Second Genome was founded in 2009.

  • Where is Second Genome headquartered?

    Second Genome is headquartered in Brisbane, CA.

  • What is the size of Second Genome?

    Second Genome has 14 total employees.

  • What industry is Second Genome in?

    Second Genome’s primary industry is Drug Discovery.

  • Is Second Genome a private or public company?

    Second Genome is a Private company.

  • What is Second Genome’s current revenue?

    The current revenue for Second Genome is .

  • How much funding has Second Genome raised over time?

    Second Genome has raised $98.8M.

  • Who are Second Genome’s competitors?

    Vedanta Biosciences, Biosortia Microbiomics, 4D pharma, Eligo Bioscience, and Sphere Fluidics are some of the 30 competitors of Second Genome.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process